HeartSciences Inc.: Form 10-Q for the period ended Jan 31, 2024
Filed with the SEC on Mar 14, 2024 and accepted by EDGAR at Mar 14, 2024, 16:05 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-01-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-11-01 to 2024-01-31 | $14.7k | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2023-05-01 to 2024-01-31 | $18.6k | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2023-11-01 to 2024-01-31 | $4.6k | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2023-05-01 to 2024-01-31 | $6.1k | us-gaap:CostOfRevenue |
| Gross profit | 3 months2023-11-01 to 2024-01-31 | $10.1k | us-gaap:GrossProfit |
| Gross profit | 9 months2023-05-01 to 2024-01-31 | $12.5k | us-gaap:GrossProfit |
| Research and development | 3 months2023-11-01 to 2024-01-31 | $509.5k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2023-05-01 to 2024-01-31 | $1.8m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2023-11-01 to 2024-01-31 | $1.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2023-05-01 to 2024-01-31 | $2.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-11-01 to 2024-01-31 | −$1.5m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2023-05-01 to 2024-01-31 | −$4.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2023-11-01 to 2024-01-31 | $118.4k | us-gaap:InterestExpense |
| Interest expense | 9 months2023-05-01 to 2024-01-31 | $333.1k | us-gaap:InterestExpense |
| Net income | 3 months2023-11-01 to 2024-01-31 | −$1.6m | us-gaap:NetIncomeLoss |
| Net income | 9 months2023-05-01 to 2024-01-31 | −$4.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-11-01 to 2024-01-31 | −$0.03 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2023-05-01 to 2024-01-31 | −$0.19 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-11-01 to 2024-01-31 | −$0.03 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2023-05-01 to 2024-01-31 | −$0.19 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-11-01 to 2024-01-31 | 53,792,741 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2023-05-01 to 2024-01-31 | 25,201,024 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2023-05-01 to 2024-01-31 | −$4.5m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2023-05-01 to 2024-01-31 | $15.7k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-01-31 | $7.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-01-31 | $8.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-01-31 | $10.8m | us-gaap:Assets |
| Current liabilities | At period end2024-01-31 | $1.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-01-31 | $2.2m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-01-31 | $8.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-24-031457. Last ingested by Listed: Nov 4, 2026, 19:48 ET. Listed shows no prices and gives no investment advice.